Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-
ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable …

Inhibition of immune regulatory checkpoints, such as CTLA-4 and the PD-1-PD-L1 axis, is at
the forefront of immunotherapy for cancers of various histological types. However, such …

Since the mid-1990s, dendritic cells have been used in clinical trials as cellular mediators for
therapeutic vaccination of patients with cancer. Dendritic cell-based immunotherapy is safe …

Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective
antitumor immune response against tumor antigens and was first explored in a clinical trial …

Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …

Dendritic cells (DCs), the most potent antigen-presenting cells, are necessary for effective
activation of naïve T cells. DCs' immunological properties are modulated in response to …

Despite the frequent detection of circulating tumor antigen–specific T cells, either
spontaneously or following active immunization or adoptive transfer, immune-mediated …

The immunotherapy of cancer has made significant strides in the past few years due to
improved understanding of the underlying principles of tumor biology and immunology …

The incidence of melanoma is increasing worldwide, and the prognosis for patients with
high‐risk or advanced metastatic melanoma remains poor despite advances in the field …

The development of therapeutic cancer vaccines as a means to generate immune reactivity
against tumors has been explored since the early discovery of tumor-specific antigens by …